Geron (GERN) Change in Acquisitions & Divestments (2010 - 2026)
Geron (GERN) posted Change in Acquisitions & Divestments of $86.6 million for Q1 2026, down 30.89% sequentially from $125.4 million in Q4 2025, and down 12.39% YoY from $98.9 million in Q1 2025.
Geron (GERN) Change in Acquisitions & Divestments (2010 - 2026) Analysis & Trends
Geron has reported Change in Acquisitions & Divestments for 17 years, with the latest figure at $86.6 million in Q1 2026.
- Quarterly Change in Acquisitions & Divestments fell 12.39% year-over-year to $86.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $399.5 million (up 7.95% YoY) and the FY2025 annual result came in at $411.7 million, up 10.79% from the prior year.
- Change in Acquisitions & Divestments fell to $86.6 million in Q1 2026 per GERN's latest filing, from $125.4 million in the prior quarter.
- Over five years, Change in Acquisitions & Divestments peaked at $179.8 million in Q4 2022 and troughed at $41.8 million in Q2 2022.
- A 5-year average of $87.4 million and a median of $86.6 million in 2026 frame the typical range for Change in Acquisitions & Divestments.
- The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments soared 2947.74% in 2022, then tumbled 64.68% in 2023.
- Over 5 years, Change in Acquisitions & Divestments stood at $179.8 million in 2022, then sank by 64.68% to $63.5 million in 2023, then increased by 27.78% to $81.1 million in 2024, then jumped by 54.51% to $125.4 million in 2025, then plunged by 30.89% to $86.6 million in 2026.
- According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $86.6 million, $125.4 million, and $90.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.42 Mn |
| Jun 30, 2026 | 97.42 Mn |
| Mar 31, 2026 | 86.63 Mn |
| Mar 31, 2026 | 86.63 Mn |
| Dec 31, 2025 | 125.36 Mn |
| Dec 31, 2025 | 125.36 Mn |
| Sep 30, 2025 | 90.29 Mn |
| Sep 30, 2025 | 90.29 Mn |
| Jun 30, 2025 | 97.18 Mn |
| Jun 30, 2025 | 97.18 Mn |
| Mar 31, 2025 | 98.88 Mn |
| Mar 31, 2025 | 98.88 Mn |
| Dec 31, 2024 | 81.14 Mn |
| Dec 31, 2024 | 81.14 Mn |
| Sep 30, 2024 | 65.25 Mn |
| Sep 30, 2024 | 65.25 Mn |
| Jun 30, 2024 | 124.78 Mn |
| Jun 30, 2024 | 124.78 Mn |
| Mar 31, 2024 | 100.44 Mn |
| Mar 31, 2024 | 100.44 Mn |